Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfac298 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Matteo Bargagli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Swiss National Science Foundation, NCCR TransCure, NCCR Kidney.
Abstract (Originalsprache)
Background
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of tolvaptan treatment on mineral metabolism and bone mineral density (BMD) is unknown.
Methods
We conducted an analysis in the Bern ADPKD Registry, a prospective observational cohort study. Mineral metabolism parameters were measured at baseline and every 12 months thereafter. BMD was determined by dual-energy X-ray absorptiometry at baseline and after 3 years. Multivariable mixed-effects regression models were applied to assess changes in mineral metabolism parameters and BMD associated with tolvaptan treatment.
Results
A total of 189 participants (122 without and 67 with subsequent tolvaptan treatment) were included in the analysis. During follow-up, tolvaptan treatment was associated with increased BMD at the femoral neck {β = 0.092 [95% confidence interval (CI) 0.001–0.183], P = .047}. In addition, tolvaptan treatment was associated with higher plasma magnesium [β = 0.019 (95% CI 0.001–0.037), P = .037], bicarbonate [β = 0.972 (95% CI 0.242–1.702), P = .009] and urine pH [β = 0.214 (95% CI 0.056–0.372), P = .008] and lower parathyroid hormone [β = −0.191 (95% CI −0.328 to −0.053), P = .006], 1,25(OH)D3 [β = −0.126 (95% CI −0.235 to −0.164), P = .024] and fractional urinary magnesium excretion [β = −0.473 (95% CI −0.622 to −0.324), P < .001].
Conclusions
Chronic tolvaptan treatment is associated with increased femoral BMD and significant changes in both mineral metabolism and acid–base parameters in ADPKD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Università Cattolica del Sacro Cuore, Rome, Italy.
- U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Förderung
- Swiss National Science Foundation
- NCCR TransCure
- NCCR Kidney
Zitieren
APA
Bargagli, M., Vetsch, A., Anderegg, M. A., Dhayat, N. A., Huynh-Do, U., Faller, N., Vogt, B., Ferraro, P. M., & Fuster, D. G. (2023). Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac298
Vancouver
Bargagli M, Vetsch A, Anderegg MA, Dhayat NA, Huynh-Do U, Faller N, et al. Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac298
BibTeX
@article{Bargagli2023,
author = {Bargagli, Matteo and Vetsch, Andri and Anderegg, Manuel A and Dhayat, Nasser A and Huynh-Do, Uyen and Faller, Nicolas and Vogt, Bruno and Ferraro, Pietro Manuel and Fuster, Daniel G},
title = {Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfac298}
}
EUVIMED